$BBIO News

BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97

BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup

Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115

Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1

Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120